Browsing Tag
RenovoCath
2 posts
How the TIGeR-PaC sub-study could influence future thinking around chemotherapy tolerability and precision delivery
RenovoRx’s TIGeR-PaC sub-study highlights how targeted chemotherapy delivery could reshape pancreatic cancer treatment strategy. Read more.
How the Japan patent allowance could strengthen RenovoRx’s oncology platform valuation story
Could RenovoRx’s Japan patent strengthen the RNXT valuation story? Read what this means for growth, competition, and investor sentiment.